Primary Care COPD Patients Compared with Large Pharmaceutically-Sponsored COPD Studies : An UNLOCK Validation Study
Annemarije L Kruis,Björn Ställberg,Rupert Jones,Ioanna Tsiligianni,Karin Lisspers,Thys van der Molen,Janwillem W. H. Kocks,Niels H. Chavannes +7 more
Reads0
Chats0
TLDR
Primary care COPD patients stand out from patients enrolled in LPCS in terms of gender, lung function, quality of life and exacerbations, as hitherto unknown GOLD I exacerbation characteristics are revealed.Abstract:
Background: Guideline recommendations for chronic obstructive pulmonary disease (COPD) are based on the results of large pharmaceutically-sponsored COPD studies (LPCS). There is a paucity of data on disease characteristics at the primary care level, while the majority of COPD patients are treated in primary care. Objective: We aimed to evaluate the external validity of six LPCS (ISOLDE, TRISTAN, TORCH, UPLIFT, ECLIPSE, POET-COPD) on which current guidelines are based, in relation to primary care COPD patients, in order to inform future clinical practice guidelines and trials. Methods: Baseline data of seven primary care databases (n = 3508) from Europe were compared to baseline data of the LPCS. In addition, we examined the proportion of primary care patients eligible to participate in the LPCS, based on inclusion criteria. Results: Overall, patients included in the LPCS were younger (mean difference (MD)-2.4; p = 0.03), predominantly male (MD 12.4; p = 0.1) with worse lung function (FEV1% MD -16.4; p = 1 and >= 2 exacerbations, although results were not statistically significant. Our findings add to the literature, as we revealed hitherto unknown GOLD I exacerbation characteristics, showing 34% of mild patients had >= 1 exacerbations per year and 12% had >= 2 exacerbations per year. The proportion of primary care patients eligible for inclusion in LPCS ranged from 17% (TRISTAN) to 42% (ECLIPSE, UPLIFT). Conclusion: Primary care COPD patients stand out from patients enrolled in LPCS in terms of gender, lung function, quality of life and exacerbations. More research is needed to determine the effect of pharmacological treatment in mild to moderate patients. We encourage future guideline makers to involve primary care populations in their recommendations.read more
Citations
More filters
Journal ArticleDOI
What have we learned from observational studies and clinical trials of mild to moderate COPD
TL;DR: There is scarce evidence from randomised clinical trials and real-life studies about the importance of pharmacological treatment in early stages of COPD to improve long-term outcomes, but new concepts such as clinically important deterioration may help to investigate the impact of interventions on the natural history of the disease.
Journal ArticleDOI
Clinical drug trials in general practice: how well are external validity issues reported?
TL;DR: The clinical setting of the trials, the selection of patients before enrolment, and co-morbidity or co-medication of participants was most commonly not reported, limiting the possibility to consider the generalizability of a trial.
Journal ArticleDOI
Defining severe obstructive lung disease in the biologic era: an endotype-based approach
TL;DR: The definition of severe obstructive lung disease must be updated so that it includes all patients who could benefit from novel treatments and for whom associated costs are justified, allowing targeted biologic therapies to benefit a greater proportion and range of patients.
Journal ArticleDOI
Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?
Martine Hoogendoorn,Talitha L Feenstra,Yumi Asukai,Andrew Briggs,Sixten Borg,Roberto W. Dal Negro,Ryan N. Hansen,Sven-Arne Jansson,Reiner Leidl,Nancy Risebrough,Yevgeniy Samyshkin,Margarethe Wacker,Maureen P.M.H. Rutten-van Mölken +12 more
TL;DR: Two models are found to be most suitable to evaluate personalized treatment in COPD by exploring the type of heterogeneity included in current models and by validating outcomes for subgroups of patients.
Journal ArticleDOI
Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients
TL;DR: An important gap exists between real-life patients and clinical trials populations in COPD, which limits the relevance of results and therefore should be considered when grading levels of evidence and designing future studies.
References
More filters
Journal ArticleDOI
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Jørgen Vestbo,Suzanne S. Hurd,Alvar Agusti,Paul W. Jones,Claus Vogelmeier,Antonio Anzueto,Peter J. Barnes,Leonardo M. Fabbri,Fernando J. Martinez,Masaharu Nishimura,Robert A. Stockley,Don D. Sin,Roberto Rodriguez-Roisin +12 more
TL;DR: It is recommended that spirometry is required for the clinical diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation.
Journal ArticleDOI
Global initiative for chronic obstructive lung disease.
Lynn B. Gerald,William C. Bailey +1 more
TL;DR: Representatives from many countries serve as a network for the dissemination and implementation of programs for diagnosis, management, and prevention of COPD.
Journal ArticleDOI
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Julie A. Anderson,Bartolome R. Celli,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Julie C. Yates,Jørgen Vestbo +6 more
TL;DR: The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance, and there were significant benefits in all other outcomes among these patients.
Journal ArticleDOI
The St George's Respiratory Questionnaire.
TL;DR: The St George's Respiratory Questionnaire is a standardized self-completed questionnaire for measuring impaired health and perceived well-being in airways disease and the background and rationale for its development are discussed together with an analysis of its performance.
Journal ArticleDOI
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
John R. Hurst,Jørgen Vestbo,Jørgen Vestbo,Antonio Anzueto,Nicholas Locantore,Hana Müllerová,Ruth Tal-Singer,Bruce E. Miller,David A. Lomas,Alvar Agusti,William MacNee,Peter M.A. Calverley,Stephen I. Rennard,Emiel F.M. Wouters,Jadwiga A. Wedzicha +14 more
TL;DR: Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype, which has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity.